140 related articles for article (PubMed ID: 19423481)
1. Compassionate use study of caspofungin in children with proven or suspected invasive mycosis or persistent febrile neutropenia.
Madero L; Sanchez de Toledo J; Castel V; Sevilla J; Gonzalez-Esteban J; Sanz-Rodriguez C
J Chemother; 2009 Apr; 21(2):229-31. PubMed ID: 19423481
[No Abstract] [Full Text] [Related]
2. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K
Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
Cesaro S; Toffolutti T; Messina C; Calore E; Alaggio R; Cusinato R; Pillon M; Zanesco L
Eur J Haematol; 2004 Jul; 73(1):50-5. PubMed ID: 15182338
[TBL] [Abstract][Full Text] [Related]
4. Modern antifungal therapy for neutropenic fever.
Corey M
Curr Hematol Malig Rep; 2006 Jun; 1(2):95-100. PubMed ID: 20425338
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin versus liposomal amphotericin B for empirical therapy.
Marty FM; Lowry CM
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675093
[No Abstract] [Full Text] [Related]
6. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
[TBL] [Abstract][Full Text] [Related]
7. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.
Tan BH; Low JG; Chlebicka NL; Kurup A; Cheah FK; Lin RT; Goh YT; Wong GC
Int J Infect Dis; 2011 May; 15(5):e350-6. PubMed ID: 21397541
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia.
Torres A; Serrano J; Rojas R; Martín V; Martín C; Tabares S; Molina JR; Capote M; Martínez F; Gómez P; Sánchez-García J
Eur J Haematol; 2010 Mar; 84(3):271-3. PubMed ID: 19878274
[No Abstract] [Full Text] [Related]
9. New antifungal drugs and the pediatric cancer patient: current status of clinical development.
Groll AH; Lehrnbecher T
Klin Padiatr; 2005; 217(3):158-68. PubMed ID: 15858708
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin therapy in immunocompromised children and neonates.
Somer A; Törün SH; Salman N
Expert Rev Anti Infect Ther; 2011 Mar; 9(3):347-55. PubMed ID: 21417874
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children.
Koo A; Sung L; Allen U; Naqvi A; Drynan-Arsenault J; Dekker A; Maloney AM; Dupuis LL
Pediatr Infect Dis J; 2007 Sep; 26(9):854-6. PubMed ID: 17721388
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
[TBL] [Abstract][Full Text] [Related]
13. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
14. [Outcome analysis of caspofungin in combination with voriconazole for treatment of 12 hematologic malignancies cases with invasive fungal infection].
Sun HL; Zhou X; Shen YF
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):558-9. PubMed ID: 22338183
[No Abstract] [Full Text] [Related]
15. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of caspofungin therapy in children with invasive fungal infections.
Merlin E; Galambrun C; Ribaud P; Blanc T; Michel G; Auvrignon A; Stéphan JL
Pediatr Infect Dis J; 2006 Dec; 25(12):1186-8. PubMed ID: 17133169
[TBL] [Abstract][Full Text] [Related]
17. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant.
Castagnola E; Machetti M; Cappelli B; Molinari AC; Morreale G; Dodero P; Tomà P; Faraci M
Clin Microbiol Infect; 2004 Mar; 10(3):255-7. PubMed ID: 15008948
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin versus liposomal amphotericin B for empirical therapy.
Danaher PJ
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
[No Abstract] [Full Text] [Related]
19. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
20. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?
Klastersky J
N Engl J Med; 2004 Sep; 351(14):1445-7. PubMed ID: 15459307
[No Abstract] [Full Text] [Related]
[Next] [New Search]